MeritValue

Karyopharm Therapeutics Inc.

KPTIdata completeness 88%15 fiscal years on file
i. The business — what you’d actually own
FigureFY 2021FY 2022FY 2023FY 2024FY 2025
Revenue$209.8M1$157.1M2$146M3$145.2M3$146.1M3
Net income−$124.1M4−$165.3M5−$143.1M6−$76.4M6−$196M6
Operating cash flow−$107.1M7−$149.6M8−$92.7M9−$127.5M9−$75.4M9
Capital expenditure$212,00010$118,00011$012$142,00012$012
Free cash flow (derived)−$107.3M7−$149.7M8−$92.7M9−$127.6M9−$75.4M9
Total debt$169.3M13————
Cash & equivalents$190.5M14$135.2M15$52.2M16$62.5M16$60.5M16
Diluted shares75.2M81,8717,6168,45510,935

Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).

ii. Your slice — ownership made literal
If you owned
shares
Net assets behind them
−$267,879.29
your share of equity
Profit it earned you last year
−$179,276.63
Free cash flow it threw off
−$68,924.55
Debt you’d be carrying
—

10 shares is a claim on −$267,879.29 of net worth that earned you −$179,276.63 and generated −$68,924.55 of cash last year.

iii. Is this a good business?
Moat signal · return on equity
— avg · 5y

Not enough data in the filings for a return-on-capital reading.

seeing a moat in the numbers →
Management signal · capital allocation
−100% shares · 5y

Share count is down 100% over 5 years — management has been buying back stock, quietly handing owners a bigger slice. Total debt has held roughly steady.

reading capital allocation →

Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.

iv. What it’s worth — engine v0.1.0
DCF · Growth Exit 10Y
not applicable
3y-median FCF non-positive — growth-exit DCF not applicable (see EPV)
DCF · Growth Exit 5Y
not applicable
3y-median FCF non-positive — growth-exit DCF not applicable (see EPV)
Earnings Power Value
not applicable
normalized (5y-median) earnings non-positive — EPV undefined
Graham Number
not applicable
diluted EPS missing or non-positive — Graham Number undefined

Different models answer different questions — which to trust when →

Sources — the receipts
  1. 10-K · period ending 2021-12-31 · accession 0000950170-24-022650 (RevenueFromContractWithCustomerExcludingAssessedTax)
  2. 10-K · period ending 2022-12-31 · accession 0000950170-25-022765 (RevenueFromContractWithCustomerExcludingAssessedTax)
  3. 10-K · period ending 2023-12-31 · accession 0001193125-26-049397 (RevenueFromContractWithCustomerExcludingAssessedTax)
  4. 10-K · period ending 2021-12-31 · accession 0000950170-24-022650 (NetIncomeLoss)
  5. 10-K · period ending 2022-12-31 · accession 0000950170-25-022765 (NetIncomeLoss)
  6. 10-K · period ending 2023-12-31 · accession 0001193125-26-049397 (NetIncomeLoss)
  7. 10-K · period ending 2021-12-31 · accession 0000950170-24-022650 (NetCashProvidedByUsedInOperatingActivities)
  8. 10-K · period ending 2022-12-31 · accession 0000950170-25-022765 (NetCashProvidedByUsedInOperatingActivities)
  9. 10-K · period ending 2023-12-31 · accession 0001193125-26-049397 (NetCashProvidedByUsedInOperatingActivities)
  10. 10-K · period ending 2021-12-31 · accession 0000950170-24-022650 (PaymentsToAcquirePropertyPlantAndEquipment)
  11. 10-K · period ending 2022-12-31 · accession 0000950170-25-022765 (PaymentsToAcquirePropertyPlantAndEquipment)
  12. 10-K · period ending 2023-12-31 · accession 0001193125-26-049397 (PaymentsToAcquirePropertyPlantAndEquipment)
  13. 10-K · period ending 2021-12-31 · accession 0000950170-22-002548 (LongTermDebt)
  14. 10-K · period ending 2021-12-31 · accession 0000950170-24-022650 (CashAndCashEquivalentsAtCarryingValue)
  15. 10-K · period ending 2022-12-31 · accession 0000950170-25-022765 (CashAndCashEquivalentsAtCarryingValue)
  16. 10-K · period ending 2023-12-31 · accession 0001193125-26-049397 (CashAndCashEquivalentsAtCarryingValue)